Disc Medicine (NASDAQ:IRON) Given New $170.00 Price Target at Cantor Fitzgerald

Disc Medicine (NASDAQ:IRON) had its target price boosted by research analysts at Cantor Fitzgerald from $125.00 to $170.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 117.20% from the company’s current price.

A number of other equities research analysts have also recently commented on IRON. Morgan Stanley reissued an “overweight” rating and set a $90.00 price target on shares of Disc Medicine in a report on Monday, August 17th. Wedbush reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Disc Medicine in a research note on Thursday, September 10th. Wall Street Zen cut Disc Medicine from a “hold” rating to a “sell” rating in a research report on Saturday. Wells Fargo & Company increased their target price on Disc Medicine from $79.00 to $86.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 16th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Disc Medicine in a research note on Thursday, September 10th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $110.40.

Disc Medicine Price Performance

Shares of IRON traded up $21.43 during trading hours on Monday, reaching $78.27. 3,940,558 shares of the stock traded hands, compared to its average volume of 589,621. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine has a 52-week low of $40.00 and a 52-week high of $99.50. The company’s 50-day moving average price is $71.55 and its two-hundred day moving average price is $71.18. The company has a market cap of $300.17 million, a P/E ratio of -11.80 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.17. On average, analysts anticipate that Disc Medicine will post -6.61 earnings per share for the current year.

Insider Activity at Disc Medicine

In related news, insider Rahul Khara sold 5,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the completion of the transaction, the insider directly owned 52,324 shares of the company’s stock, valued at approximately $4,185,920. This trade represents a 8.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO John D. Quisel sold 33,000 shares of Disc Medicine stock in a transaction on Monday, August 17th. The shares were sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the completion of the sale, the chief executive officer owned 226,064 shares in the company, valued at approximately $17,892,965.60. This represents a 12.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 131,221 shares of company stock worth $10,239,760 in the last three months. Insiders own 3.76% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Arizona State Retirement System grew its position in shares of Disc Medicine by 2.4% during the second quarter. Arizona State Retirement System now owns 6,844 shares of the company’s stock valued at $501,000 after purchasing an additional 160 shares in the last quarter. AlphaCentric Advisors LLC increased its holdings in shares of Disc Medicine by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock worth $254,000 after purchasing an additional 216 shares during the last quarter. State of Wyoming purchased a new stake in shares of Disc Medicine in the second quarter worth about $25,000. Entropy Technologies LP lifted its position in shares of Disc Medicine by 9.9% in the first quarter. Entropy Technologies LP now owns 4,788 shares of the company’s stock worth $306,000 after buying an additional 431 shares in the last quarter. Finally, Allworth Financial LP purchased a new stake in shares of Disc Medicine in the second quarter worth about $46,000. Institutional investors own 83.70% of the company’s stock.

Key Stories Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Bitopertin met the primary objective and all key goals in the Phase 3 APOLLO trial, strengthening the case that the drug could become a potential disease-modifying treatment for EPP. Disc Medicine’s rare disease drug succeeds in late-stage trial
• Positive Sentiment: Disc Medicine said it plans to resubmit bitopertin to the U.S. Food and Drug Administration, creating a significant regulatory catalyst following the successful trial. Disc Medicine’s Bitopertin Meets All Phase 3 Goals; FDA Resubmission Planned
• Positive Sentiment: The late-stage result removes a major clinical risk for IRON and drove a sharp rally as investors reassessed the commercial potential of the Roche-originated drug. Disc Medicine surges on late-stage trial win for lead asset developed with Roche
• Positive Sentiment: Bitopertin could address substantial unmet need because no disease-modifying therapy for EPP is currently approved, although the product remains investigational. Disc Medicine Says Metabolic Disorder Drug Meets Main Goal in Phase 3 Trial
• Neutral Sentiment: Disc Medicine scheduled an investor webcast to discuss the APOLLO topline data, giving investors additional details on efficacy, safety and the planned FDA filing. Disc Medicine to Host Corporate Webcast
• Negative Sentiment: Risks remain around FDA review, potential approval timing, commercialization costs and the company’s reliance on bitopertin as its primary value driver.
• Negative Sentiment: Recent reports questioned IRON’s valuation relative to book value, while disclosed insider activity showed selling and no purchases over the cited six-month period, which may weigh on sentiment. Disc Medicine Stock Still Looks Pricey As Book Value Lags Expectations

About Disc Medicine

Disc Medicine, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving the production of red blood cells, iron metabolism and heme biology, areas that can contribute to anemia and other blood-related complications.

Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule therapy designed to modulate glycine transporter 1 and influence heme production. The company is evaluating bitopertin in conditions including erythropoietic protoporphyria, a rare disorder associated with painful light sensitivity, as well as polycythemia vera and other hematologic diseases.

The company is also developing additional therapies intended to regulate iron availability and address anemia associated with chronic or hematologic conditions.